BeNeLuxBelgiumNetherlandsLuxembourg

Deal for Parkinson pair

03.11.2010

Brussels – Biopharma giant UCB Group has secured exclusive rights to two drug candidates for treating Parkinson’s disease from Swiss drug developer Synosia Therapeutics AG. Synosia will receive an undisclosed upfront payment and is eligible for up to US$ 725m (EUR517m) in milestones plus royalties. The Swiss firm will be responsible for Phase II development, while UCB will take on Phase III development and commercialisation. UCB led the financing with a US$ 20m (EUR14.3m) investment. SYN-115 is an adenosine A2A receptor inhibitor Synosia obtained from Hoffmann-La Roche (Basel) three years ago. It is designed to work as an oral pill with the rare ability to cross the blood-brain barrier. The second candidate is SYN-118, a 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor. The two drug candidates are both currently in Phase II testing for PD. With the deal, UCB wants to further strengthen its neurology port­folio.

BeNeLuxBelgiumNetherlandsLuxembourg

07.09.2011

Diepenbeek - Amakem has received €18m to take a glaucoma drug candidate through Phase II trials. The Belgium-based developer lead candidate will use the money to advance its lead candidate AMA0076 to the clinical proof of...

BeNeLuxBelgiumNetherlandsLuxembourg

01.09.2011

New York - US-American investment firm OrbiMed announced the closing of a new fund for life science companies in the health sector. The fund acquires healthcare royalty streams and provides structured debt capital to healthcare...

BeNeLuxBelgiumNetherlandsLuxembourg

31.08.2011

Leiden/Stockholm – Dutch Pharming Group NV and Swedish specialist for rare diseases Orphan Biovitrum AB, have launched their recombinant C1 inhibitor Ruconest® in the Netherlands. The launch of the treatment for patients...

BeNeLuxBelgiumNetherlandsLuxembourg

22.08.2011

Leuven – ThromboGenics NV presented promising results of its Ocriplasmin Phase III clinical program at the Annual Meeting of the American Society of Retina Specialists (ASRS). „We remain on track to make regulatory filings for...

BeNeLuxBelgiumNetherlandsLuxembourg

18.08.2011

Liège – A Belgian research team from the University of Liège’s GIGA-Research centre has discovered an unexpected mode of action for the vaccine adjuvant alum. The team discovered that when a vaccine containing alum is injected...

BeNeLuxBelgiumNetherlandsLuxembourg

16.08.2011

Amsterdam – Dutch molecular diagnostics specialist Agendia B.V. postponed its initial public offering in June because of volatile market conditions, revealing that the financing environment for bio­tech firms remains tough....

BeNeLuxBelgiumNetherlandsLuxembourg

11.07.2011

Dutch gene therapy specialist Amsterdam Molecular Therapeutics BV (AMT) has filed a re-examination request for its lead product Glybera. At the end of June, EMA's CHMP recommended against approval of the product to treat...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Ghent – The Flanders Institute for Biotechnology VIB will receive EUR3m from the European Commission for the recruitment and training of promising international scientists in the life sciences. This will allow VIB to further...

Displaying results 31 to 40 out of 304

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/3/article/deal-for-parkinson-pair.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THROMBOGENICS (B)9.54 EUR-5.07%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.77 EUR-29.2%
  • PROSENSA (NL)9.81 USD-22.6%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products